# Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
Canonical URL: https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-positive-results-from-the-enlighten-2-phase-3-trial-of-lyr-210-achieving-statistically-significant-results-for-primary-and-key-secondary-endpoints-in-the-treatment-of-chronic-rhinosinusitis-crs
Ticker: LYRA
Company: Lyra Therapeutics
Source: Lyra Therapeutics
Published: 2025-06-02 11:00 EST
Original Source URL: https://investors.lyratherapeutics.com
## Summary

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically significant improvement in key secondary endpoints in the full

## Article Body
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically significant improvement in key secondary endpoints in the full
## Recent Company News
- 2026-04-17 12:00 EST — [Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-inc-announces-intention-to-voluntarily-file-form-25-for-delisting-from-nasdaq-and-subsequent-deregistration-with-the-sec) — Source: Lyra Therapeutics
- 2026-01-12 12:00 EST — [Lyra Therapeutics Provides Corporate Update](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-provides-corporate-update) — Source: Lyra Therapeutics
- 2025-11-12 21:01 EST — [Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update) — Source: Lyra Therapeutics
- 2025-10-06 11:00 EST — [Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-announces-clinical-plan-for-lyr-210-and-late-breaking-oral-presentation-of-phase-3-enlighten-2-study) — Source: Lyra Therapeutics
- 2025-08-12 20:01 EST — [Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/LYRA/lyra-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update) — Source: Lyra Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)